drugset / Trial / NCT04693026
Efficacy of Ramdicivir and Baricitinib for the Treatment of Severe COVID 19 Patients
Phase 3
Unknown
150 enrolled
M Abdur Rahim Medical College and Hospital
First Affiliated Hospital Xi'an Jiaotong University · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
This study was designed to evaluate the efficacy of Remdesivir and Baricitinib combination therapy for the treatment of severe Acute Respiratory Distress Syndrome (ARDS) caused by Coronavirus disease 2019 (COVID-19). Our aim is to compare the outcome of the "Remdesivir + Baricitinib" combination against "Remdesivir + Tocilizumab" therapy and find the best option for the management of ARDS in COVID-19 patients.
Timeline
- Start
- 2020-09-10
- Primary completion
- 2021-02-15
- Completion
- 2021-03-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Baricitinib | Small molecule | 4 mg | Oral |
| Subject | Remdesivir | Small molecule | 2.5 mg/kg | Intravenous |
| Subject | Remdesivir | Small molecule | 100 mg | Intravenous |
| Comparator | Tocilizumab | Monoclonal antibody | 8 mg/kg | Intravenous |